关键词: font-size:medium, ">还原型谷胱甘肽；异烟肼；利福平；药物性肝损伤；临床疗效；安全性

Abstract: Objective： To investigate the clinical efficacy and safety of reduced glutathione injection in the treatment of isoniazid and rifampicin-induced drug-induced liver injury.Methods：From June 2022 to June 2024， 80 patients with liver injury occurring during treatment with isoniazid and rifampicin admitted to our hospital were enrolled and divided into a control group(n=40) and an experimental group(n=40) using a convenient grouping method. The control group was treated with polyene phosphatidylcholine， while the experimental group received additional reduced glutathione based on the control group′s treatment regimen. Both groups were treated for 4 weeks， and clinical efficacy， liver function， liver fibrosis indicators， and incidence of adverse reactions were observed.Results： After intervention， the effective rate in the experimental group was 95.00%， higher than 80.00% in the control group(P<0.05). After intervention， liver function indicators including AST， ALT， ALP， GGT， and TBIL decreased in both groups， with lower levels in the experimental group compared to the control group(P<0.05). After intervention， liver fibrosis indicators including PC-Ⅲ， Ⅳ-C， LN， and HA decreased in both groups， with lower levels in the experimental group compared to the control group(P<0.05). During treatment， the incidence of adverse reactions in the experimental group was 2.5%， lower than 20.00% in the control group(P<0.05).Conclusion：Reduced glutathione injection demonstrates significant clinical efficacy and high safety in the treatment of isoniazid and rifampicin-induced drug-induced liver injury， warranting further promotion and application in clinical practice.

Key words: font-size:medium, ">Reduced glutathione； Isoniazid； Rifampicin； Drug-induced liver injury； Clinical efficacy； Safety